Taysha Gene Therapies (TSHA) Retained Earnings (2019 - 2026)
Taysha Gene Therapies (TSHA) posted Retained Earnings of -$753.7 million for Q1 2026, down 5.96% sequentially from -$711.3 million in Q4 2025, and down 20.82% YoY from -$951.9 million in Q1 2025.
Taysha Gene Therapies (TSHA) Retained Earnings (2019 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Retained Earnings for 8 years, with the latest figure at -$753.7 million in Q1 2026.
- Quarterly Retained Earnings fell 20.82% year-over-year to -$753.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$753.7 million (down 20.82% YoY) and the FY2025 annual result came in at -$711.3 million, down 204.93% from the prior year.
- Retained Earnings eased to -$753.7 million in Q1 2026 per TSHA's latest filing, from -$711.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at $677.9 million in Q4 2024 and troughed at -$753.7 million in Q1 2026.
- A 5-year average of -$113.0 million and a median of -$285.8 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings soared 247.9% in 2023, then sank 29257.77% in 2025.
- Over 5 years, Retained Earnings stood at $402.4 million in 2022, then surged by 46.11% to $587.9 million in 2023, then grew by 15.29% to $677.9 million in 2024, then slumped by 204.93% to -$711.3 million in 2025, then declined by 5.96% to -$753.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$753.7 million, -$711.3 million, and -$683.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 1.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.19 Bn |
| Mar 31, 2026 | -753.71 Mn |
| Dec 31, 2025 | -711.30 Mn |
| Sep 30, 2025 | -683.45 Mn |
| Jun 30, 2025 | -650.70 Mn |
| Mar 31, 2025 | -623.83 Mn |
| Dec 31, 2024 | 677.86 Mn |
| Sep 30, 2024 | -2.33 Mn |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | -537.10 Mn |
| Dec 31, 2023 | 587.94 Mn |
| Sep 30, 2023 | 511.63 Mn |
| Jun 30, 2023 | 406.55 Mn |
| Mar 31, 2023 | 404.11 Mn |
| Dec 31, 2022 | 402.39 Mn |
| Sep 30, 2022 | -345.94 Mn |
| Jun 30, 2022 | -319.60 Mn |
| Mar 31, 2022 | -285.80 Mn |
| Dec 31, 2021 | 331.03 Mn |
| Sep 30, 2021 | -185.30 Mn |